
Quarterly report 2022-Q4
added 02-09-2023
Cardiovascular Systems Net Income 2011-2026 | CSII
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -36.9 M | -13.4 M | -27.2 M | -255 K | 1.71 M | -1.79 M | -56 M | -32.8 M | -35.3 M | -24 M | -16.8 M | -11.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.71 M | -56 M | -21.2 M |
Quarterly Net Income Cardiovascular Systems
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.89 M | -10.6 M | -18.5 M | -9.66 M | -8.97 M | -8.62 M | -17.6 M | -8.62 M | -56 K | -2.08 M | -56 K | -2.89 M | -3.4 M | -3.4 M | -3.4 M | -5.78 M | 492 K | 492 K | 492 K | -2.89 M | -413 K | -1.98 M | -413 K | -1.98 M | 1.04 M | -1.86 M | 1.04 M | -1.86 M | -15.2 M | -13.3 M | -15.2 M | -13.3 M | -5.27 M | -8.22 M | -5.27 M | -8.22 M | -8.66 M | -7.29 M | -8.66 M | -7.29 M | -5.77 M | -12.2 M | -5.77 M | -5.21 M | -4.14 M | -3.86 M | -4.14 M | -3.86 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.04 M | -18.5 M | -5.83 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aziyo Biologics
AZYO
|
-37.7 M | - | 1.37 % | $ 20.5 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | ||
|
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | ||
|
Cutera
CUTR
|
-57.2 M | - | -10.19 % | $ 1.99 M | ||
|
Bruker Corporation
BRKR
|
113 M | $ 38.78 | -1.25 % | $ 5.78 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | ||
|
Acutus Medical
AFIB
|
-81.7 M | - | -26.83 % | $ 2.62 M | ||
|
Dynatronics Corporation
DYNT
|
-10.9 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-157 M | - | - | $ 10.2 M | ||
|
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | ||
|
Cognyte Software Ltd.
CGNT
|
-12.1 M | $ 8.15 | 4.22 % | $ 585 M | ||
|
Second Sight Medical Products
EYES
|
-23.5 M | - | -0.97 % | $ 54.4 M | ||
|
AdaptHealth Corp.
AHCO
|
-70.8 M | $ 9.69 | 3.09 % | $ 1.31 B | ||
|
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
-19 M | $ 4.15 | 4.01 % | $ 155 M | ||
|
Electromed
ELMD
|
7.54 M | $ 24.26 | 1.17 % | $ 205 M | ||
|
CONMED Corporation
CNMD
|
47.1 M | $ 43.13 | -0.43 % | $ 1.34 B | ||
|
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | ||
|
FONAR Corporation
FONR
|
12.4 M | $ 18.51 | 0.05 % | $ 121 M | ||
|
AxoGen
AXGN
|
-15.7 M | $ 29.17 | -2.21 % | $ 1.34 B | ||
|
Apyx Medical Corporation
APYX
|
-18.7 M | $ 3.31 | 4.42 % | $ 115 M | ||
|
Axonics Modulation Technologies
AXNX
|
-59.7 M | - | - | $ 3.31 B | ||
|
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B | ||
|
Accuray Incorporated
ARAY
|
-1.59 M | $ 0.53 | 0.68 % | $ 54.5 M | ||
|
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M | ||
|
Medigus Ltd.
MDGS
|
4.05 M | - | 10.28 % | $ 55.5 M | ||
|
Cytosorbents Corporation
CTSO
|
-20.7 M | $ 0.79 | -1.24 % | $ 43 M | ||
|
Align Technology
ALGN
|
421 M | $ 183.14 | 0.27 % | $ 13.7 B | ||
|
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | ||
|
Inari Medical
NARI
|
-29.3 M | - | - | $ 4.23 B | ||
|
Butterfly Network
BFLY
|
-72.5 M | $ 3.99 | 7.7 % | $ 845 M | ||
|
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K | ||
|
Abbott Laboratories
ABT
|
6.52 B | $ 113.59 | 0.01 % | $ 198 B | ||
|
NuVasive
NUVA
|
40.4 M | - | - | $ 2.07 B | ||
|
Nevro Corp.
NVRO
|
-113 M | - | - | $ 217 M | ||
|
InMode Ltd.
INMD
|
93.8 M | $ 13.58 | -0.18 % | $ 878 M | ||
|
BioSig Technologies
BSGM
|
-10.3 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
2.89 B | $ 72.75 | -1.49 % | $ 108 B | ||
|
IRadimed Corporation
IRMD
|
19.2 M | $ 105.22 | 0.89 % | $ 1.33 B | ||
|
IRIDEX Corporation
IRIX
|
-9.57 M | $ 1.42 | -0.7 % | $ 22.9 M | ||
|
Helius Medical Technologies
HSDT
|
-8.85 M | $ 2.31 | 16.67 % | $ 1.4 M | ||
|
Alphatec Holdings
ATEC
|
-143 M | $ 13.05 | 0.23 % | $ 1.96 B | ||
|
Edwards Lifesciences Corporation
EW
|
1.07 B | $ 85.73 | 0.55 % | $ 50.1 B |